Patient characteristics
| UPN . | Sex . | Age (y) . | ISS Stage . | Durie and Salmon . | Light chain restriction . | Cytogenetic risk . | Previous therapy . | HLA typing . | Experiment . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 62 | 3 | 3B | λ | High | Yes | A*26, A*30, B*15, B*42 | Q; L |
| 2 | F | 55 | 2 | 1A | Non | Standard | No | A*01, A*24, B*18, B*08 | L |
| 3 | F | 69 | 2 | 3B | κ | Standard | No | A*02, A*01, B*08, B*37 | L |
| 4 | M | 72 | 3 | 3A | κ | Standard | No | A*02, A*33, B*15, B*18 | L |
| 5 | M | 54 | 2 | 3A | κ | Low | No | A*03, A*26, B*40, B*55 | L |
| 6 | M | 60 | 3 | 3B | λ | High | No | A*02, A*24, B*07, B*27 | L |
| 7 | F | 39 | 3 | 3A | κ | Standard | No | A*02, A*03, B*07, B*35 | L |
| 8 | F | 73 | 3 | 3B | λ | Unknown | No | A*24, A*25, B*39, B*40 | L |
| 9 | M | 52 | 3 | 1B | κ | Unknown | No | A*02, B*07, B*44 | L |
| 10 | M | 47 | 1 | 3A | κ | Standard | No | A*03, A*33, B*07 | L |
| 11 | F | 72 | 2 | 3A | κ | High | Yes | A*02, B*27, B*44 | Q |
| 12 | F | 68 | 2 | 3A | κ | Standard | No | n.d. | Q |
| 13 | M | 74 | 1 | 3A | κ | Standard | No | n.d. | Q |
| 14 | F | 50 | 1 | 3A | λ | Standard | No | A*01, A*68, B*08, B*35 | Q |
| 15 | M | 62 | 1 | 3A | κ | Standard | Yes | n.d. | Q |
| 16 | M | 74 | 3 | 2B | κ | Standard | Yes | n.d. | Q |
| 17 | M | 68 | 1 | 3A | κ | Unknown | Yes | A*03, A*33, B*14, B*18 | Q |
| 18 | M | 73 | 1 | 1A | κ | Standard | Yes | A*02, A*32, B*40, B*44 | Q |
| 19 | F | 70 | 1 | 1A | κ | Standard | No | n.d. | Q |
| 20 | F | 53 | 3 | 3A | κ | Standard | No | n.d. | Q |
| 21 | M | 59 | 2 | 3A | λ | Standard | Yes | n.d. | Q |
| 22 | M | 57 | 1 | 1A | κ | Standard | Yes | n.d. | Q |
| 23 | F | 65 | 3 | 1A | λ | Standard | Yes | n.d. | Q |
| 24 | M | 76 | 2 | 3A | λ | Standard | Yes | n.d. | Q |
| 25 | F | 74 | 2 | 2A | κ | Standard | Yes | A*01, A*02, B*08, B*44 | Q |
| 26 | F | 67 | 1 | 3A | λ | Standard | Yes | n.d. | Q |
| 27 | M | 50 | 1 | 1A | λ | Unkwnon | Yes | A*01, A*03, B*35, B*40 | Q |
| 28 | M | 70 | 3 | 3A | λ | Unknown | No | n.d. | Q |
| 29 | M | 75 | 1 | 3A | κ | Standard | Yes | n.d. | Q |
| UPN . | Sex . | Age (y) . | ISS Stage . | Durie and Salmon . | Light chain restriction . | Cytogenetic risk . | Previous therapy . | HLA typing . | Experiment . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 62 | 3 | 3B | λ | High | Yes | A*26, A*30, B*15, B*42 | Q; L |
| 2 | F | 55 | 2 | 1A | Non | Standard | No | A*01, A*24, B*18, B*08 | L |
| 3 | F | 69 | 2 | 3B | κ | Standard | No | A*02, A*01, B*08, B*37 | L |
| 4 | M | 72 | 3 | 3A | κ | Standard | No | A*02, A*33, B*15, B*18 | L |
| 5 | M | 54 | 2 | 3A | κ | Low | No | A*03, A*26, B*40, B*55 | L |
| 6 | M | 60 | 3 | 3B | λ | High | No | A*02, A*24, B*07, B*27 | L |
| 7 | F | 39 | 3 | 3A | κ | Standard | No | A*02, A*03, B*07, B*35 | L |
| 8 | F | 73 | 3 | 3B | λ | Unknown | No | A*24, A*25, B*39, B*40 | L |
| 9 | M | 52 | 3 | 1B | κ | Unknown | No | A*02, B*07, B*44 | L |
| 10 | M | 47 | 1 | 3A | κ | Standard | No | A*03, A*33, B*07 | L |
| 11 | F | 72 | 2 | 3A | κ | High | Yes | A*02, B*27, B*44 | Q |
| 12 | F | 68 | 2 | 3A | κ | Standard | No | n.d. | Q |
| 13 | M | 74 | 1 | 3A | κ | Standard | No | n.d. | Q |
| 14 | F | 50 | 1 | 3A | λ | Standard | No | A*01, A*68, B*08, B*35 | Q |
| 15 | M | 62 | 1 | 3A | κ | Standard | Yes | n.d. | Q |
| 16 | M | 74 | 3 | 2B | κ | Standard | Yes | n.d. | Q |
| 17 | M | 68 | 1 | 3A | κ | Unknown | Yes | A*03, A*33, B*14, B*18 | Q |
| 18 | M | 73 | 1 | 1A | κ | Standard | Yes | A*02, A*32, B*40, B*44 | Q |
| 19 | F | 70 | 1 | 1A | κ | Standard | No | n.d. | Q |
| 20 | F | 53 | 3 | 3A | κ | Standard | No | n.d. | Q |
| 21 | M | 59 | 2 | 3A | λ | Standard | Yes | n.d. | Q |
| 22 | M | 57 | 1 | 1A | κ | Standard | Yes | n.d. | Q |
| 23 | F | 65 | 3 | 1A | λ | Standard | Yes | n.d. | Q |
| 24 | M | 76 | 2 | 3A | λ | Standard | Yes | n.d. | Q |
| 25 | F | 74 | 2 | 2A | κ | Standard | Yes | A*01, A*02, B*08, B*44 | Q |
| 26 | F | 67 | 1 | 3A | λ | Standard | Yes | n.d. | Q |
| 27 | M | 50 | 1 | 1A | λ | Unkwnon | Yes | A*01, A*03, B*35, B*40 | Q |
| 28 | M | 70 | 3 | 3A | λ | Unknown | No | n.d. | Q |
| 29 | M | 75 | 1 | 3A | κ | Standard | Yes | n.d. | Q |
Cytogenetic risk according to the IMWG risk stratification.44
F, female; IMWG, International Myeloma Working Group; ISS, International Staging System; L, HLA ligand isolation; M, male; n.d., not determined; Q, HLA quantification; UPN, uniform patient number; y, years.